Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Charles Degenhardt (NPI 1467651711)

Field	Value
Entity Type	Individual
Organization	Charles Degenhardt
Address	5400 Waters Ave
City	Savannah
State	GA
ZIP	31404
Taxonomy	Rheumatology Physician
NPI Enumerated	July 17, 2007

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider is effectively a single‑payer Medicare practice: lifetime Medicare revenue is $2.4M and there is no Medicaid billing on file, so Medicaid contributes $0 to the documented payer mix and the practice’s commercial/Medicaid exposure is essentially absent in these records. That concentration means the provider’s revenue profile is driven almost exclusively by Medicare-paid biologic and infusion services rather than by dual-payer volumes.

Revenue concentration is high and centered on physician‑administered biologics: the precomputed top 3 Medicare codes by revenue account for 77.8% of this provider's total Medicare revenue, with J0129 ($909.5K, 37.6%), J1602 ($681.6K, 28.2%), and J9312 ($289.3K, 12.0%) together dominating the revenue mix. This indicates the practice’s financials are heavily dependent on a small set of high-cost injectable drugs administered in the practice setting.

The code mix and utilization pattern point to an infusion‑centric rheumatology practice: high revenue and volume for J0129 (abatacept), J1602 (golimumab, IV), and J9312 (rituximab) paired with a notably high rank for 96365 (initial IV infusion; ranks #196 of 8873, 98th percentile; notably above typical national volume) suggest routine in-office IV biologic administration and infusion management as core services. The presence of add‑on infusion codes (96415) and multiple laboratory immunology tests (86200, 86480) supports a workflow oriented around infusion visits with associated diagnostic monitoring.

Competitive standing is mixed by code: the provider is a major national volume contributor for J1602 (ranks #15 of 1041, 99th percentile; notably above typical national volume) and is also well above typical national volume for J0129 (ranks #67 of 1221, 95th percentile; notably above typical national volume), indicating outsized market share in those specific biologics. By contrast, J9312 (ranks #83 of 317, 74th percentile; typical, unremarkable volume) and several other codes are at typical or modest national positions, so the provider’s dominance is concentrated in a small number of drugs rather than across a broad set of services.

Clinical visit volume (E/M) is present but not the primary revenue driver: 99214 accounts for $40K (1.7% of Medicare revenue) and ranks #55952 of 479517 (88th percentile), showing above‑average E/M claim counts nationally but a small share of revenue relative to biologic drug billing. This pattern implies clinical management and follow‑up visits support therapy administration rather than generating the bulk of income.

Tenure and credentials are long‑standing: the NPI was enumerated on 2007-07-17 (~19 years ago), indicating nearly two decades of enrollment in Medicare which supports established referral relationships and operational experience with in‑office infusion workflows. This longevity helps explain the high ranks on select infusion and biologic codes.

Operational exposure is concentrated in physician‑administered biologics and infusion throughput: with J0129, J1602, and J9312 making up the majority of Medicare revenue and strong utilization of infusion administration code 96365, the practice’s revenue is sensitive to changes in Medicare drug reimbursement, site‑of‑service rules, or shifts to self‑administered formulations. Absent any Medicaid billing, any policy or payer changes affecting Medicare drug administration would have an outsized effect on this provider’s topline.

Several other service lines and labs are billed at typical volumes (examples: J0717, J3262, 99205, 86235), indicating routine rheumatology diagnostics and occasional procedures rather than broad procedural diversification. These ancillary codes contribute small portions of revenue and reinforce the interpretation that the practice is focused on biologic therapy delivery with standard rheumatologic follow‑up and testing.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	26,750	$30	$909.5K
J1602	Injection, golimumab, 1 mg, for intravenous use	68,160	$10	$681.6K
J9312	Injection, rituximab, 10 mg	4,520	$60	$289.3K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	48,000	$1	$192K
J3262	Injection, tocilizumab, 1 mg	27,280	$10	$136.4K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1,850	$30	$48.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	460	$90	$40K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	690	$50	$32.5K
J0897	Injection, denosumab, 1 mg	1,260	$20	$22.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	180	$90	$16.9K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Charles Degenhardt — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	3	30	9,660	$30	$403.6K
J9312	7	10	4,620	$60	$307.4K
J1602	1	30	17,200	$10	$240.1K
J3262	11	10	45,840	$1	$233.4K
J0717	5	20	38,000	$1	$199.3K
J1745	18	30	2,160	$30	$96.6K
J0897	232	290	2,460	$20	$90.2K
86235	14	20	310	$20	$49.5K
96413	73	160	170	$90	$20.3K
99214	1,798	13,640	120	$80	$17.8K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Charles Degenhardt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
William Chafin	GA	Rheumatology Physician	$3.3M	$0
Christopher Michaelis	SC	Emergency Medicine Physician	$3.3M	$0
Taylor Mader	SC	Rheumatology Physician	$3.1M	$0
Dean Stephens	GA	Rheumatology Physician	$2.7M	$0
David Lazar	SC	Rheumatology Physician	$2.7M	$0
Paul Sutej	GA	Rheumatology Physician	$2.4M	$0
Durga Adhikari	SC	Rheumatology Physician	$2.4M	$0
Marta Bognar	GA	Rheumatology Physician	$2.3M	$0
Brent Flickinger	GA	Rheumatology Physician	$2.3M	$0
David Chetrit	SC	Rheumatology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Charles Degenhardt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Georgia Emergency Physician Specialists	GA	Emergency Medicine Physician	$0	$12.7M
Savannah Children's Heart Center, PC	GA	Pediatric Cardiology Physician	$0	$10.2M
Pediatric Associates Of Savannah, P.C.	GA	Pediatrics Physician	$0	$8.8M
Robin Ray	GA	Ophthalmology Physician	$3.5M	$0
Robert King	GA	Ophthalmology Physician	$3.4M	$0
Mppg, Inc.	GA	Family Medicine Physician	$0	$2.8M
Anchor Medical LLC	GA	Durable Medical Equipment & Medical Supplies	$0	$2.8M
Atlantic Radiology Associates, LLC	GA	Diagnostic Radiology Physician	$0	$2.3M
Georgia Eye Surgicenter, LLC	GA	Ambulatory Surgical Clinic/Center	$1.9M	$0
Jennifer Yannucci	GA	Hematology & Oncology Physician	$1.7M	$0

Charles Degenhardt — Billing Profile & Reimbursement Data

Sign up for Charles Degenhardt — Billing Profile & Reimbursement Data policy alerts

Charles Degenhardt — Billing Profile & Reimbursement Data

Sign up for Charles Degenhardt — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References